ImmunoPrecise Antibodies Ltd. Announces AI-Designed GLP-1 Peptides Surpassing Semaglutide in Receptor Activation ImmunoPrecise Antibodies Ltd. $(IPA)$ has announced new in vitro results for its AI-designed GLP-1 receptor agonist peptides, which have shown comparable or superior receptor activation to Semaglutide, a leading GLP-1 therapy. The analysis, conducted by an independent third party, highlights the potential of AI in generating functionally validated peptide drugs. The company is exploring two preclinical paths for its GLP-1 candidates: injectable delivery studies and non-invasive delivery strategies, such as transdermal patches and nucleic acid-based delivery systems. These developments align with ImmunoPrecise's goals of enhancing therapeutic durability, patient compliance, and ease of administration. The results, demonstrating the efficacy of the HYFT-driven design approach, have already been presented, marking a significant step in AI-powered drug discovery with applications extending to other therapeutic areas.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.